Macugen (pegaptanib)
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 54 (Table of Contents)
Published: 4 Dec-2004
DOI: 10.3833/pdr.v2004.i54.746 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
There are currently over 20 different compounds in the process of development for treating back-of-the-eye diseases, but Macugen™ looks to be victorious as the first major competitor for Novartis’ and QLT’s Visudyne®, which has had free reign in the wet age related macular degeneration (AMD) market since it was launched in 2000...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS